GLP-1 Pill Foundayo Shown to Significantly Alleviate Obstructive Sleep Apnea in Clinical Trial

New clinical trial data reveals that Foundayo, an oral GLP-1 receptor agonist developed by Eli Lilly, markedly reduces symptoms of obstructive sleep apnea, a condition linked to obesity and characterized by repeated breathing interruptions during sleep. The findings suggest potential broader therapeutic benefits beyond weight management, including improved cardiovascular health due to reduced oxygen deprivation episodes. Eli Lilly plans to submit the drug for FDA approval as a treatment for sleep apnea later this year.
In November 2026, new clinical trial data published in the Journal of the American Medical Association revealed that Foundayo (orforglipron), an oral GLP-1 receptor agonist developed by Eli Lilly, significantly reduced the severity of obstructive sleep apnea (OSA) in adults with obesity. After 52 weeks of treatment, participants without positive airway pressure (PAP) therapy experienced a 43.8% reduction in OSA severity, while those using PAP machines saw a 27.5% improvement. All participants lost approximately 28 pounds on average, underscoring the drug’s dual impact on weight and respiratory function. The findings are particularly notable because they extend beyond Foundayo’s existing FDA approval for obesity treatment in April 2026, suggesting potential repurposing for a major sleep disorder affecting an estimated 936 million adults globally—many undiagnosed. The study was led by researchers including Vaishnavi Kundel from Mount Sinai and supported by Daniel Drucker, an endocrinologist with prior consulting ties to Eli Lilly, who emphasized the drug’s potential cardiovascular benefits due to reduced oxygen deprivation episodes during sleep.
Eli Lilly is now preparing to submit Foundayo for FDA approval as a treatment for moderate to severe OSA in overweight or obese adults by year-end. This move builds on earlier evidence that injectable GLP-1 drugs—like semaglutide—also improve OSA symptoms, but Foundayo’s oral formulation could offer a more accessible alternative for patients who prefer daily pills over injections. The company stands to expand its market reach beyond weight management into the $20 billion global sleep apnea treatment sector, which currently relies heavily on PAP devices. However, long-term safety data, especially regarding cardiovascular outcomes, remains under scrutiny, as Drucker noted concerns about the broader implications of modifying the GLP-1 pathway. What remains unknown is whether Foundayo will achieve similar results in diverse populations or whether its benefits persist beyond one year without continued use.
Foundayo’s potential approval could significantly shift how obstructive sleep apnea is managed, particularly for patients who struggle with adherence to PAP therapy—often cited as a major barrier to treatment. If proven effective and safe, an oral GLP-1 medication may reduce reliance on cumbersome devices, improving quality of life and potentially lowering healthcare costs tied to untreated OSA, such as hypertension and stroke. This could impact insurance providers, sleep clinics, and medical device manufacturers, whose business models depend on PAP machine use. A comparable precedent is the rise of semaglutide for diabetes and weight loss, which disrupted traditional treatment pathways and spurred widespread adoption despite initial skepticism. Foundayo may follow a similar trajectory, though its success will depend on real-world effectiveness and long-term safety data not yet available. What to watch for next includes post-approval monitoring, potential pricing strategies, and whether other pharmaceutical companies accelerate development of oral GLP-1 therapies for sleep disorders. The broader implication is that metabolic drugs may increasingly treat conditions beyond their original indications—reshaping how medicine approaches chronic, multifactorial diseases.